Haisco Pharmaceutical Group (002653) Q2 2025 earnings summary

Executive summary

• Achieved a fund unit net value of 1.3325 RMB as of June 30, 2025, with a net value growth rate of 17.63% for the first half of 2025, outperforming the benchmark's 8.22% growth rate.

• The fund focused on domestic demand and technology growth sectors, with tactical shifts to precious and industrial metals amid tariff uncertainties.

• Maintained compliance and robust internal controls, with no regulatory violations or abnormal trading detected during the period.

Financial highlights

• Net profit for the period was RMB 16,642,379.49, with realized income of RMB 12,426,829.16.

• Fund assets under management at period end were RMB 103,559,244.33, with a cumulative net value growth rate since inception of 47.46%.

• Major sources of income included stock investment gains (RMB 11,871,668.04), bond investment gains (RMB 103,007.57), and dividend income (RMB 1,183,251.42).

Outlook and guidance

• The second half of 2025 is expected to see stable macroeconomic performance, with focus on "anti-involution" policies and continued global monetary easing.

• Investment strategy will emphasize high-dividend, low-valuation stocks and sectors with mid-term growth or disruptive potential.